Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)

NCT00466258 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00466258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00466258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)
Lead sponsor
PETHEMA Foundation
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2006
Completion date
November 30, 2009
Enrollment
50 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, hiv infections